[1]张东卫.氨磺必利与利培酮治疗晚发性精神分裂症的疗效和安全性比较[J].新乡医学院学报,2023,40(6):534-537.[doi:10.7683/xxyxyxb.2023.06.006]
　ZHANG Dongwei.Comparison of efficacy and safety between amisulpride and risperidone in the treatment of late-onset schizophrenia[J].Journal of Xinxiang Medical University,2023,40(6):534-537.[doi:10.7683/xxyxyxb.2023.06.006]
点击复制

氨磺必利与利培酮治疗晚发性精神分裂症的疗效和安全性比较
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
40卷
期数:
2023年6
页码:
534-537
栏目:
临床研究
出版日期:
2023-06-05

文章信息/Info

Title:
Comparison of efficacy and safety between amisulpride and risperidone in the treatment of late-onset schizophrenia
作者:
张东卫
（新乡医学院第二附属医院心身医学科，河南　新乡　453002）
Author(s):
ZHANG Dongwei
（Department of Psychosomatic Medicine,the Second Affiliated Hospital of Xinxiang Medical University,Xinxiang 453002,Henan Province,China）
关键词:
氨磺必利; 利培酮; 精神分裂症; 阳性和阴性症状量表
Keywords:
amisulpride; risperidone; schizophrenia; positive and negative symptoms scale
分类号:
R749.3
DOI:
10.7683/xxyxyxb.2023.06.006
文献标志码:
A
摘要:
目的　比较氨磺必利与利培酮治疗晚发性精神分裂症的疗效和安全性。方法　选择2018年3月至2019年9月新乡医学院第二附属医院收治的62例晚发性精神分裂症患者为研究对象。根据治疗方法将患者分为氨磺必利组（n=32）和利培酮组（n=30）。氨磺必利组患者给予氨磺必利治疗，起始剂量为50 mg·d-1，分2次口服，依照病情变化1周内逐渐增加至治疗剂量，治疗剂量范围为100~800 mg·d-1；利培酮组患者给予利培酮治疗，起始剂量为1 mg·d-1，分2次口服，1周内逐渐增加至治疗剂量，治疗剂量范围为2~5 mg·d-1。2组患者均连续治疗6周。治疗前和治疗6周时，采用阳性和阴性症状量表（PANSS）评估2组患者的精神症状严重程度和临床疗效，并计算治疗总有效率。采用治疗伴发症状量表（TESS）评估2组患者的不良反应程度。观察并记录2组患者不良反应发生情况，并计算不良反应总发生率。结果　氨磺必利组和利培酮组患者的治疗总有效率分别为96.87%（31/32）、96.67%（29/30）；2组患者的治疗总有效率比较差异无统计学意义（χ2=0.122，P>0.05）。 治疗前及治疗6周时，2组患者的PANSS评分比较差异无统计学意义（P>0.05）；氨磺必利组和利培酮组患者治疗6周时的PANSS评分均显著低于治疗前（P<0.05）。治疗6周时，氨磺必利组患者的TESS评分显著低于利培酮组（P<0.05）。氨磺必利组患者的体质量增加、催乳素升高、急性肌张力障碍、静坐不能发生率显著低于利培酮组（χ2=31.270、29.650、3.687，P<0.05）。2组患者的心电图QTc间期延长、肝功能异常发生率比较差异无统计学意义（χ2=1.071、0.879，P>0.05）。结论　氨磺必利与利培酮治疗晚发性精神分裂症患者的临床效果相当，采用氨磺必利治疗的患者体质量增加、催乳素升高及急性肌张力障碍、静坐不能等不良反应较少。
Abstract:
Objective　To compare the efficacy and safety of amisulpride and risperidone in the treatment of late-onset schizophrenia.Methods　A total of 62 patients with late onset schizophrenia admitted to the Second Affiliated Hospital of Xinxiang Medical University from March 2018 to September 2019 were selected as the study subjects.According to the treatment method,the patients were divided into the amisulpride group (n=32) and the risperidone group (n=30).The patients in the amisulpride group were treated with amisulpride at an initial dose of 50 mg · d-1,taken orally in two doses,gradually increasing to the treatment dose within a week according to changes in the condition,with a treatment dose range of 100-800 mg · d-1;the patients in the risperidone group were treated with risperidone at an initial dose of 1 mg · d-1,administered orally in two doses,gradually increasing to the treatment dose within a week,with a treatment dose range of 2-5 mg · d-1.The patients in the two groups were treated continuously for 6 weeks.Before treatment and at 6 weeks of treatment,the severity of mental symptoms and clinical efficacy of patients in the two groups were evaluated by the positive and negative symptoms scale (PANSS),and the total effective of treatment was calculated.The degree of adverse reactions of patients in the two groups was evaluated by the treatment emergent symptom scale (TESS).The occurrence of adverse reactions of patients in the two groups was observed and recorded,and the total incidence rate of adverse reactions was calculated.Results　The total effective rates of patients in the amisulpride group and the risperidone group were 96.87% (31/32) and 96.67% (29/30),respectively;there was no significant difference in the total effective rate of patients between the two groups（χ2=0.122，P>0.05）.There was no significant difference in PANSS scores of patients between the two groups before treatment and at 6 weeks of treatment (P>0.05);the PANSS scores of patients in the amisulpride group and risperidone group at 6 weeks of treatment were significantly lower than before treatment (P<0.05).At 6 weeks of treatment,the TESS score of patients in the amisulpride group was significantly lower than that in the risperidone group (P<0.05).The incidence of increased body mass,elevated prolactin,acute muscle tone disorders,and inability to sit still of patients in the amisulpride group were significantly lower than those in the risperidone group（χ2=31.270,29.650,3.687;P<0.05）.There was no significant difference in the incidences of prolonged QTc interval and abnormal liver function of patients between the two groups（χ2=1.071,0.879;P>0.05）.Conclusion　The clinical effect of amisulpride and risperidone in the treatment of late-onset schizophrenia is comparable,and there are fewer adverse reactions such as increased body mass,elevated prolactin,acute muscle tone disorders and inability to sit still in patients treated with amisulpride.

参考文献/References:

［1］　JOHNSEN E,KROKEN R A,LBERG E M,et al.Amisulpride,aripiprazole,and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro):a pragmatic,rater-blind,semi-randomised trial［J］.Lancet Psychiatry,2020,7(11):945-954.
［2］　FILTS Y,LITMAN R E,MARTNEZ J,et al.Long-term efficacy and safety of once-monthly Risperidone ISM? in the treatment of schizophrenia:results from a 12-month open-label extension stud［J］.Schizophr Res,2022,239:83-91.
［3］　陈丽萍，陈晓岗.晚发精神分裂症的研究进展［J］.国际精神病学杂志,2013,40(2):92-94.
CHEN L P,CHEN X G.Research progress in late onset schizophrenia［J］.J Int Psychl,2013,40(2):92-94.
［4］　DIETZ A G,GOLDMAN S A,NEDERGAARD M.Glial cells in schizophrenia:a unified hypothesis［J］.Lancet Psychiatry,2020,7(3):272-281.
［5］　FOLSTEIN M F，FOLSTEIN S E，MCHUGH P R.“Mini-mental state”.A practical method for grading the cognitive state of patients for the clini-cian［J］.J Psychiatr Res,1975,12(3):189-198.
［6］　汤毓华.心理卫生评定量表手册（增订版）［M］.北京：中国心理卫生杂志社,1999:220-223.
TANG Y H.Rating scales for mental health (revised version) ［M］.Beijing:China Journal of Mental Health,1999:220-223.
［7］　孙新宇,于欣,沈渔邨.早晚发精神分裂症患者临床和神经心理特征比较［J］.中国心理卫生杂志,2007,21(4):263-266.
SUN X Y,YU X,SHEN Y C.Comparative study on clinical and neuropsychological characteristics in patients with early-onset and late-onset schizophrenia［J］.Chin Mental Health J,2007,21(4):263-266.
［8］　KAHN R S,WINTER VAN ROSSUM I,LEUCHT S,et al.Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE):a three-phase switching study［J］.Lancet Psychiatry,2018,5(10):797-807.
［9］　李宁,季卫东,张冬红,等.晚发性精神分裂症患者幻听与负性情感、事件相关电位关系研究［J］.中国现代医学杂志,2007,17(5):613-615.
LI N,JI W D,ZHANG D H,et al.Study on late schizophrenia and negative feelings and auditory event-related potential［J］.Chin J Mod Med,2007,17(5):613-615.
［10］　生丽婷.氨磺必利与利培酮治疗首发精神分裂症疗效和安全性的对照研究［J］.中国医药指南,2020,18(3):148-149.
SHEGN L T.A comparative study on the efficacy and safety of amisulpiride and risperidone in the treatment of first-episode schizophrenia［J］.Guide China Med,2020,18(3):148-149.
［12］　SCHMIDT-KRAEPELIN C,FEYERABEND S,ENGELKE C,et al.A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE):methods and design［J］.Eur Arch Psychiatry Clin Neurosci,2020,270(1):83-94.
［13］　TOLEDO-ROMERO F,MOLINA J D,LPEZ-RODRGUEZ E,et al.Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy［J］.Pharmacopsychiatry,2015,48(2):51-57.
［14］　李洁,姚贵忠,刘丽娟,等.非典型抗精神病药物相关代谢不良反应的系统评价和 meta分析［J］.中国心理卫生杂志,2015(3):210-216.
LI J,YAO G Z,LIU L J,et al.A systematic review and meta-analysis of metabolic side effects of atypical antipsychoties［J］.Chin Mental Health J,2015(3):210-216.
［15］　ROIX J J,DECRESCENZO G A,CHEUNG P H,et al.Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion［J］.Diabetes Obes Metab,2012,14(4):329-334.
［16］　陶晶,李清伟.抗精神病药物所致高泌乳素血症相关研究进展［J］.中华全科医师杂志,2018,17(4):329-331.
TAO J,LI Q W.Research progress of hyperprolactinemia induced by antipsychotic drugs［J］.Chin J Gen Pract,2018,17(4):329-331.
［17］　杨栋.抗精神病药物引起高泌乳素血症的相关研究及临床管理策略［J］.现代医药卫生,2018,34(10):1505-1508.
YAGN D.Related research and clinical management strategies of hyperprolactinemia caused by antipsychotic drugs［J］.J Mod Med Health,2018,34(10):1505-1508.
［18］　GLATARD A,GUIDI M,DELACRTAZ A,et al.Amisulpride:real-world evidence of dose adaptation and effect on prolactin concentrations and body weight gain by pharmacokinetic/pharmacodynamic analyses［J］.Clin Pharmacokinet,2020,59(3):371-382.
［19］　王蜀湘,马玲,张利.第二代抗精神病药物对心电图和脑电图的影响［J］.新疆医学,2014(4):66-67.
WANG S X,MA L,ZHANG L.The effect of second-generation antipsychotic drugs on electrocardiogram and electroencephalogram［J］.Xinjiang Med J,2014(4):66-67.
［20］　张海军,唐其柱.抗精神病药对精神分裂症患者QTc间期的影响［J］.西北药学杂志,2021,36(5):797-802.
ZHAGN H J,TANG Q Z.Influence of antipsychotic drugs on QTc interval in patients with schizophrenia［J］.Northwest Pharmaceut J,2021,36(5):797-802.
［21］　FOX G M,ALBAYATY M,WALKER J L,et al.Intravenous amisulpride does not meaningfully prolong the QTc interval at doses effective for the management of postoperative nausea and vomiting［J］.Anesth Analg,2021,132(1):150-159.
［22］　曹莉莎,王继生,张芳,等.631例抗精神病药物药品不良反应分析［J］.中国药物警戒,2022,19(3):322-324.
CAO H S,WANG J S,ZHANG F,et al.Adverse drug reactions caused by antipsychotic drugs in 631 cases［J］.Chin J Pharmacov,2022,19(3):322-324.
［23］　REEVES S,EGGLESTON K,CORT E,et al.Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP)［J］.Int J Geriatr Psychiatry,2018,33(2):396-404.
（

相似文献/References:

[1]郭慧荣,张绍荣． 孙富根.利培酮与氯氮平治疗精神分裂症的临床对照研究[J].新乡医学院学报,2001,18(03):174.
[2]扬世昌,祁富生,张疆丽.利培酮治疗精神分裂症2O例[J].新乡医学院学报,2002,19(02):113.
[3]史　晗,赵晶媛,杨勇锋,等.阿立哌唑联合利培酮治疗对男性精神分裂症患者血清催乳素及糖脂代谢的影响[J].新乡医学院学报,2018,35(6):469.[doi:10.7683/xxyxyxb.2018.06.005]
　SHI Han,ZHAO Jing-yuan,YANG Yong-feng,et al.Effect of aripiprazole combined with risperidone on serum prolactin and glucose lipid metabolism in male patients with schizophrenia[J].Journal of Xinxiang Medical University,2018,35(6):469.[doi:10.7683/xxyxyxb.2018.06.005]

更新日期/Last Update: 2023-06-05